Ipca Labs aims to make plants US FDA-compliant by December
The US FDA had banned imports to the US from Ipca's Pithampur and Silvassa plants
Mumbai: Ipca Laboratories Ltd is aiming to make all of its plants facing import alerts from the US compliant with US Food and Drug Administration (FDA) rules by December, an executive said on Wednesday.
It was not immediately clear who made the remarks, which came in an analyst conference call with Ipca’s managing director Premchand Godha and company secretary Harish Kamath.
The US FDA had banned imports to the US from Ipca’s Pithampur and Silvassa plants.
The US regulator had in January banned imports from a separate central Indian manufacturing plant of Ipca, citing violations of standard production practices. Reuters
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!